<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01363232</url>
  </required_header>
  <id_info>
    <org_study_id>CMEK162X2101</org_study_id>
    <secondary_id>2011-001083-22</secondary_id>
    <nct_id>NCT01363232</nct_id>
  </id_info>
  <brief_title>Safety, Pharmacokinetics and Pharmacodynamics of BKM120 Plus MEK162 in Selected Advanced Solid Tumor Patients</brief_title>
  <official_title>A Phase Ib, Open-label, Multi-center, Dose-escalation and Expansion Study of an Orally Administered Combination of BKM120 Plus MEK162 in Adult Patients With Selected Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Array Biopharma, now a wholly owned subsidiary of Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Array BioPharma</source>
  <brief_summary>
    <textblock>
      This is an open label, dose finding, phase Ib clinical trial to determine the maximum&#xD;
      tolerated dose (MTD) and/or the recommended phase II dose (RP2D) of the orally administered&#xD;
      phosphatidylinositol 3'-kinase (PI3K) inhibitor BKM120 in combination with the MEK1/2&#xD;
      inhibitor MEK162. This combination will be explored in patients with epidermal growth factor&#xD;
      receptor (EGFR) mutant non-small cell lung cancer (NSCLC) which has progressed on EGFR&#xD;
      inhibitors and triple negative breast cancer, as well as pancreatic cancer, colorectal&#xD;
      cancer, malignant melanoma, NSCLC, and other advanced solid tumors with KRAS, NRAS, and/or&#xD;
      BRAF mutations. Dose escalation will be guided by a Bayesian logistic regression model with&#xD;
      overdose control. At MTD or RP2D, two expansion arms will be opened in order to further&#xD;
      assess safety and preliminary anti-tumor activity of the combination of BKM120 and MEK162.&#xD;
&#xD;
      Study drugs will be administered once daily orally on a continuous schedule. A treatment&#xD;
      cycle is defined as 28 days.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">December 18, 2017</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Dose Limiting Toxicities</measure>
    <time_frame>during Cycle 1 of treatment with BKM120 and MEK162</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events and serious adverse events.</measure>
    <time_frame>from Cycle 1 Day 1 until treatment discontinuation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate, duration of response, time to response and progression free survival</measure>
    <time_frame>every 8 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time versus plasma concentration profiles of BKM120 and MEK162</measure>
    <time_frame>during the first cycle of treatment on Cycle 1 Day 1 and Cycle 1 Day 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment -induced PI3K and MEK/ERK pathway signaling inhibition and evidence of biological activity in tumor.</measure>
    <time_frame>during the first cycle of treatment on Cycle 1 Day 15 and at disease progression</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">89</enrollment>
  <condition>Advanced Solid Tumors</condition>
  <condition>Selected Solid Tumors</condition>
  <arm_group>
    <arm_group_label>BKM120 + MEK162</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BKM120 + MEK162</intervention_name>
    <arm_group_label>BKM120 + MEK162</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically/ cytologically confirmed, advanced non resectable solid tumors&#xD;
&#xD;
          -  Measurable or non-measurable, but evaluable disease as determined by RECIST&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with primary CNS tumor or CNS tumor involvement.&#xD;
&#xD;
          -  Diabetes mellitus&#xD;
&#xD;
          -  Unacceptable ocular/retinal conditions&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>1-800-718-1021</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital Mass General 2</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute Study Coordinator</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center MSKCC (2)</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Centers of the Carolinas CCC Faris</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas/MD Anderson Cancer Center MD Anderson PSC</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigative Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigative Site</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigative Site</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigative Site</name>
      <address>
        <city>Utrecht</city>
        <zip>3584CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigative Site</name>
      <address>
        <city>Singapore</city>
        <zip>169610</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigative Site</name>
      <address>
        <city>Bellinzona</city>
        <zip>6500</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Singapore</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>May 24, 2011</study_first_submitted>
  <study_first_submitted_qc>May 31, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 1, 2011</study_first_posted>
  <last_update_submitted>September 30, 2020</last_update_submitted>
  <last_update_submitted_qc>September 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>BKM120</keyword>
  <keyword>MEK162</keyword>
  <keyword>RAS RAF mutations</keyword>
  <keyword>triple negative breast cancer</keyword>
  <keyword>pancreatic cancer, ovarian cancer</keyword>
  <keyword>NSCLC progressed on EGFR TKI</keyword>
  <keyword>PI3K inhibitor</keyword>
  <keyword>MEK inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

